[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PT2927213T - Derivados da piperidinona como inibidores da mdm2 para o tratamento do cancro - Google Patents

Derivados da piperidinona como inibidores da mdm2 para o tratamento do cancro

Info

Publication number
PT2927213T
PT2927213T PT15159363T PT15159363T PT2927213T PT 2927213 T PT2927213 T PT 2927213T PT 15159363 T PT15159363 T PT 15159363T PT 15159363 T PT15159363 T PT 15159363T PT 2927213 T PT2927213 T PT 2927213T
Authority
PT
Portugal
Prior art keywords
cancer
treatment
mdm2 inhibitors
piperidinone derivatives
piperidinone
Prior art date
Application number
PT15159363T
Other languages
English (en)
Inventor
mcintosh Joel
David Bartberger Michael
Gonzalez Buenrostro Ana
Chen Xiaoqi
Victor Connors Richard
Duquette Jason
Eksterowicz John
Fisher Benjamin
Matthew Fox Brian
Fu Jiasheng
Fu Zice
William Gribble Michael
Anne Heath Julie
Huang Xin
Johnson Michael
Kayser Frank
Li Yihong
Li Zhihong
Liu Jiwen
Mcgee Lawrence
Mcminn Dustin
Thomas Mihalic Jeffrey
Howard Olson Steven
Rew Yosup
Sun Daqing
Wang Yingcai
Yan Xuelei
Yu Ming
Zhu Jiang
Plake Beck Hilary
DEIGNAN Jeffery
Gonzalez Lopez De Turiso Felix
James Gustin Darin
Jiao Xianjun
John Kopecky David
Lai Sujen
Dante Low Jonathan
Stuart Lucas Brian
Ma Zhihua
Cesar Medina Julio
Marley Roveto Philip
Wang Xiaodong
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44504412&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2927213(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of PT2927213T publication Critical patent/PT2927213T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/02—1,2-Thiazines; Hydrogenated 1,2-thiazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/153—Ortho-condensed systems the condensed system containing two rings with oxygen as ring hetero atom and one ring with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT15159363T 2010-06-04 2011-06-03 Derivados da piperidinona como inibidores da mdm2 para o tratamento do cancro PT2927213T (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35182710P 2010-06-04 2010-06-04
US35232210P 2010-06-07 2010-06-07
US201161452578P 2011-03-14 2011-03-14

Publications (1)

Publication Number Publication Date
PT2927213T true PT2927213T (pt) 2019-02-21

Family

ID=44504412

Family Applications (3)

Application Number Title Priority Date Filing Date
PT117265819T PT2576510E (pt) 2010-06-04 2011-06-03 Derivados da piperidinona como inibidores da mdm2 para o tratamento do cancro
PT15159363T PT2927213T (pt) 2010-06-04 2011-06-03 Derivados da piperidinona como inibidores da mdm2 para o tratamento do cancro
PT181971557T PT3483143T (pt) 2010-06-04 2011-06-03 Derivados da piperidinona como inibidores da mdm2 para o tratamento do cancro

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT117265819T PT2576510E (pt) 2010-06-04 2011-06-03 Derivados da piperidinona como inibidores da mdm2 para o tratamento do cancro

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT181971557T PT3483143T (pt) 2010-06-04 2011-06-03 Derivados da piperidinona como inibidores da mdm2 para o tratamento do cancro

Country Status (42)

Country Link
US (9) US8569341B2 (pt)
EP (4) EP2576510B1 (pt)
JP (3) JP5420797B2 (pt)
KR (8) KR20190058694A (pt)
CN (2) CN103180296B (pt)
AR (1) AR082763A1 (pt)
AU (1) AU2011261263C1 (pt)
BR (2) BR112012030923B8 (pt)
CA (4) CA3157177C (pt)
CL (2) CL2012003415A1 (pt)
CO (1) CO6710897A2 (pt)
CR (1) CR20120659A (pt)
CY (1) CY1121265T1 (pt)
DK (3) DK2927213T3 (pt)
EA (1) EA023004B1 (pt)
ES (3) ES2717306T3 (pt)
FI (1) FI3483143T3 (pt)
HK (3) HK1182711A1 (pt)
HR (3) HRP20240055T1 (pt)
HU (2) HUE066050T2 (pt)
IL (6) IL277579B (pt)
JO (1) JO2998B1 (pt)
LT (2) LT2927213T (pt)
MA (1) MA34342B1 (pt)
ME (2) ME03322B (pt)
MX (2) MX343587B (pt)
MY (1) MY202394A (pt)
NZ (2) NZ604074A (pt)
PE (1) PE20130229A1 (pt)
PH (1) PH12016501048A1 (pt)
PL (3) PL3483143T3 (pt)
PT (3) PT2576510E (pt)
RS (3) RS58366B1 (pt)
SG (4) SG10202006923RA (pt)
SI (3) SI3483143T1 (pt)
SM (1) SMT201500168B (pt)
TN (1) TN2012000559A1 (pt)
TW (3) TWI433844B (pt)
UA (1) UA110481C2 (pt)
UY (2) UY39338A (pt)
WO (1) WO2011153509A1 (pt)
ZA (1) ZA201400948B (pt)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0811643D0 (en) 2008-06-25 2008-07-30 Cancer Rec Tech Ltd New therapeutic agents
JO2998B1 (ar) * 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
US20130267699A1 (en) 2011-06-24 2013-10-10 California Institute Of Technology Quaternary heteroatom containing compounds
US8822679B2 (en) * 2011-06-24 2014-09-02 California Institute Of Technology Quaternary heteroatom containing compounds
WO2013049250A1 (en) * 2011-09-27 2013-04-04 Amgen Inc. Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer
DK2771320T3 (en) 2011-10-24 2016-10-03 Endo Pharmaceuticals Inc Cyclohexylamines
WO2013169531A1 (en) 2012-05-09 2013-11-14 Boehringer Ingelheim International Gmbh Methods for making oxetan-3-ylmethanamines
BR112015013611A2 (pt) 2012-12-20 2017-11-14 Merck Sharp & Dohme composto, e, composição farmacêutica
MX362896B (es) * 2013-02-19 2019-02-22 Amgen Inc Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cáncer.
US11407721B2 (en) 2013-02-19 2022-08-09 Amgen Inc. CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
EP2961735B1 (en) * 2013-02-28 2017-09-27 Amgen Inc. A benzoic acid derivative mdm2 inhibitor for the treatment of cancer
CA2906538C (en) 2013-03-14 2021-02-02 Ana Gonzalez Buenrostro Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer
JOP20200296A1 (ar) * 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط
HUE059351T2 (hu) * 2013-11-11 2022-11-28 Amgen Inc MDM2 inhibitort és egy vagy több további gyógyszerhatóanyagot tartalmazó kombinációs terápia rákbetegségek kezelésére
MX370618B (es) * 2013-12-05 2019-12-17 Hoffmann La Roche Nuevo tratamiento de combinacion para la leucemia mieloide aguda (lma).
CN111718354A (zh) 2014-04-17 2020-09-29 密歇根大学董事会 Mdm2抑制剂和使用其的治疗方法
CN103992334A (zh) * 2014-05-29 2014-08-20 中国人民解放军第二军医大学 吲哚酮螺四氢硫代吡喃类抗肿瘤衍生物及其制备方法
WO2016001376A1 (en) 2014-07-03 2016-01-07 Boehringer Ingelheim International Gmbh New spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
CA2956129C (en) 2014-08-21 2022-10-25 Boehringer Ingelheim International Gmbh New spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
US10421696B2 (en) 2014-12-18 2019-09-24 California Institute Of Technology Enantioselective synthesis of α-quaternary mannich adducts by palladium-catalyzed allylic alkylation
US10106479B2 (en) 2015-03-27 2018-10-23 California Institute Of Technology Asymmetric catalytic decarboxylative alkyl alkylation using low catalyst concentrations and a robust precatalyst
GB201517216D0 (en) 2015-09-29 2015-11-11 Cancer Res Technology Ltd And Astex Therapeutics Ltd Pharmaceutical compounds
GB201517217D0 (en) 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
JP6602470B2 (ja) * 2015-10-09 2019-11-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｍｄｍ２−ｐ５３阻害薬としてのスピロ［３ｈ−インドール−３，２‘−ピロリジン］−２（１ｈ）−オン化合物及び誘導体
EP3426391A4 (en) 2016-03-11 2019-08-28 California Institute of Technology COMPOSITIONS AND METHODS FOR ACYLATING LACTAMEN
RU2743432C2 (ru) * 2016-04-06 2021-02-18 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган Деструкторы белка mdm2
CA3020541A1 (en) * 2016-04-12 2017-10-19 The Regents Of The University Of Michigan Bet protein degraders
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
ES2858151T3 (es) 2016-05-20 2021-09-29 Hoffmann La Roche Conjugados de PROTAC-anticuerpo y procedimientos de uso
GB201704965D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
GB201704966D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
EP3480190B1 (en) 2017-11-01 2023-01-04 California Institute of Technology Methods for enantioselective allylic alkylation of esters, lactones, and lactams with unactivated allylic alcohols
EP3759090A1 (en) 2018-03-02 2021-01-06 Inflazome Limited Novel compounds
TW202146387A (zh) 2018-04-30 2021-12-16 美商卡托斯醫療公司 治療癌症之方法
SG11202101886VA (en) * 2018-08-31 2021-03-30 Amgen Inc Processes for preparing a mdm2 inhibitor
CN110963958A (zh) * 2018-09-30 2020-04-07 上海长森药业有限公司 一种mdm2抑制剂，及其制备方法、药物组合物和应用
US11214568B2 (en) 2018-10-18 2022-01-04 California Institute Of Technology Gem-disubstituted pyrrolidines, piperazines, and diazepanes, and compositions and methods of making the same
EP3927344A4 (en) * 2018-12-11 2023-01-18 Kartos Therapeutics METHODS AND COMPOSITIONS FOR THE TREATMENT OF AN EYE CONDITION
GB201919219D0 (en) 2019-12-23 2020-02-05 Otsuka Pharma Co Ltd Cancer biomarkers
EP4041736A4 (en) * 2020-01-23 2023-06-07 Ascentage Pharma (Suzhou) Co., Ltd. AMORPHOUS FORM OR CRYSTALLINE FORM OF 2-INDOLINOLINOLOLYLSPIRONONE COMPOUNDS OR THEIR SALTS, SOLVENT COMPLEXES
US20230143596A1 (en) 2020-02-27 2023-05-11 Syngenta Crop Protection Ag Pesticidally active diazine-bisamide compounds
TW202214248A (zh) 2020-08-27 2022-04-16 日商大塚製藥股份有限公司 使用ｍｄｍ２拮抗劑的癌症療法之生物標記
CN112213428A (zh) * 2020-10-13 2021-01-12 辽宁科技大学 一种超临界co2中进行非催化乙酰基化反应及其在线检测方法
GB202103080D0 (en) 2021-03-04 2021-04-21 Otsuka Pharma Co Ltd Cancer biomarkers
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
WO2023230059A1 (en) * 2022-05-24 2023-11-30 Newave Pharmaceutical Inc. Mdm2 degrader
TW202404588A (zh) * 2022-06-06 2024-02-01 美商凱麥拉醫療公司 Mdm2降解劑及其用途
CN115322126B (zh) * 2022-09-13 2023-04-28 九江学院 一种多芳烃类化合物及其制备方法和应用

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1016828A (en) 1961-11-13 1966-01-12 Mcneilab Inc Substituted morpholines and process for preparing same
DE3246148A1 (de) 1982-12-14 1984-06-14 Troponwerke GmbH & Co KG, 5000 Köln Pyrazolo(4.3-b)(1.4)oxazine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO1995023135A1 (en) 1991-03-07 1995-08-31 Fisons Corporation Diphenyl-2-piperidinone and -2-pyrrolidinone derivatives having anti-convulsant and neuroprotective activity
US5334720A (en) 1991-03-07 1994-08-02 Fisons Corporation Diphenyl-1-(aminoalkyl)-2-piperidinone and -2-pyrrolidinone derivatives having anticonvulsant properties
AU711832B2 (en) 1994-08-19 1999-10-21 Abbvie Bahamas Ltd. Endothelin antagonists
PT885215E (pt) 1996-02-13 2006-08-31 Abbott Lab Novos derivados de pirrolidina substituidos com benzo-1,3-dioxolilo e benzofuranilo como antagonistas de endotelina
US6159990A (en) 1997-06-18 2000-12-12 Synaptic Pharmaceutical Corporation Oxazolidinones as α1A receptor antagonists
TR200000993T2 (tr) 1997-08-04 2000-12-21 Abbott Laboratories Endotelin antagonistleri.
AU1910299A (en) 1997-12-18 1999-07-05 Eli Lilly And Company Peptidomimetic template-based combinatorial libraries
US6770658B2 (en) 1998-09-09 2004-08-03 Inflazyme Pharmaceuticals Ltd. Substituted γ-phenyl-Δ-lactams and uses related thereto
US7214540B2 (en) 1999-04-06 2007-05-08 Uab Research Foundation Method for screening crystallization conditions in solution crystal growth
US6630006B2 (en) 1999-06-18 2003-10-07 The Regents Of The University Of California Method for screening microcrystallizations for crystal formation
US7052545B2 (en) 2001-04-06 2006-05-30 California Institute Of Technology High throughput screening of crystallization of materials
US7195670B2 (en) 2000-06-27 2007-03-27 California Institute Of Technology High throughput screening of crystallization of materials
WO2002017912A1 (en) 2000-08-31 2002-03-07 Abbott Laboratories Endothelin antagonists
WO2002042731A2 (en) 2000-11-20 2002-05-30 Parallel Synthesis Technologies, Inc. Methods and devices for high throughput crystallization
JP2004518688A (ja) 2001-01-30 2004-06-24 ブリストル−マイヤーズ　スクイブ　カンパニー ファクターＸａ阻害剤のスルホンアミドラクタムおよびその方法
WO2002089738A2 (en) 2001-05-08 2002-11-14 Yale University Proteomimetic compounds and methods
WO2002094787A1 (en) 2001-05-23 2002-11-28 Ucb, S.A. 2-oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivativ es for the treatment of epilepsy and other neurological disorders
RU2305095C2 (ru) 2001-12-18 2007-08-27 Ф.Хоффманн-Ля Рош Аг Цис-2,4,5-трифенилимидазолины и фармацевтическая композиция на их основе
US6860940B2 (en) 2002-02-11 2005-03-01 The Regents Of The University Of California Automated macromolecular crystallization screening
US6916833B2 (en) * 2003-03-13 2005-07-12 Hoffmann-La Roche Inc. Substituted piperidines
US7425638B2 (en) 2003-06-17 2008-09-16 Hoffmann-La Roche Inc. Cis-imidazolines
KR20080027969A (ko) 2004-05-18 2008-03-28 에프. 호프만-라 로슈 아게 신규 ｃｉｓ-이미다졸린
US7893278B2 (en) 2004-06-17 2011-02-22 Hoffman-La Roche Inc. CIS-imidazolines
EA012181B1 (ru) 2004-10-18 2009-08-28 Амген, Инк. Соединения тиадиазола и их применение
CA2599476A1 (en) 2005-03-16 2006-09-21 F. Hoffmann-La Roche Ag Cis-2,4,5-triaryl-imidazolines and their use as anti-cancer medicaments
EP1871368B1 (en) 2005-04-04 2011-06-08 Eisai R&D Management Co., Ltd. Dihydropyridine compounds for neurodegenerative diseases and dementia
RU2442779C2 (ru) 2005-12-01 2012-02-20 Ф. Хоффманн-Ля Рош Аг Производные 2,4,5-трифенилимидазолина как ингибиторы взаимодействия между белками p53 и mdm2, предназначенные для применения в качестве противораковых средств
JP2009525954A (ja) * 2006-01-13 2009-07-16 シェーリング コーポレイション Ｃｂ１モジュレーターとしてのジアリールピペリジン
MY149143A (en) 2006-01-18 2013-07-15 Amgen Inc Thiazole compounds as protien kinase b (pkb) inhibitors
US20070213341A1 (en) 2006-03-13 2007-09-13 Li Chen Spiroindolinone derivatives
GB0606283D0 (en) 2006-03-29 2006-05-10 Cyclacel Ltd Process
US7884107B2 (en) * 2006-06-30 2011-02-08 Merck Substituted piperidines that increase P53 activity and the uses thereof
AU2007275805A1 (en) 2006-07-19 2008-01-24 University Of Georgia Research Foundation, Inc. Pyridinone diketo acids: Inhibitors of HIV replication in combination therapy
WO2008021338A2 (en) 2006-08-15 2008-02-21 Wyeth Tricyclic oxazolidone derivatives useful as pr modulators
WO2008021339A2 (en) 2006-08-15 2008-02-21 Wyeth Pyrrolidine and related derivatives useful as pr modulators
US8820639B2 (en) 2006-11-03 2014-09-02 Assa Abloy Ab Security feature RFID card
TW200831080A (en) 2006-12-15 2008-08-01 Irm Llc Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
EP2137150A1 (en) * 2007-03-12 2009-12-30 Biolipox AB Piperidinones useful in the treatment of inflammation
GB0722769D0 (en) 2007-11-21 2008-01-02 Biolipox Ab New compounds
RS53151B (en) 2007-03-23 2014-06-30 Amgen Inc. 3-SUBSTITUTED QUINOLINE OR QUINOXALINE DERIVATIVES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITOR (PI3K)
CA2681136C (en) 2007-03-23 2012-05-22 Amgen Inc. Heterocyclic compounds and their uses
EP2132207A2 (en) 2007-03-23 2009-12-16 Amgen Inc. Heterocyclic compounds and their uses
AR065860A1 (es) * 2007-03-29 2009-07-08 Novartis Ag 3-imidazolil-indoles para el tratamiento de enfermedades proliferativas
US7625895B2 (en) 2007-04-12 2009-12-01 Hoffmann-Le Roche Inc. Diphenyl-dihydro-imidazopyridinones
WO2008130614A2 (en) 2007-04-20 2008-10-30 University Of Pittsburg-Of The Commonwealth System Of Higher Education Selective and dual-action p53/mdm2/mdm4 antagonists
US7834179B2 (en) * 2007-05-23 2010-11-16 Hoffmann-La Roche Inc. Spiroindolinone derivatives
WO2009004430A1 (en) 2007-06-29 2009-01-08 Pfizer Inc. N-benzyl oxazolidinones and related heterocycleic compounds as potentiators of glutamate receptors
US8138183B2 (en) 2007-07-09 2012-03-20 Astrazeneca Ab Morpholino pyrimidine derivatives used in diseases linked to mTOR kinase and/or PI3K
US7919504B2 (en) 2007-07-17 2011-04-05 Amgen Inc. Thiadiazole modulators of PKB
US7897619B2 (en) 2007-07-17 2011-03-01 Amgen Inc. Heterocyclic modulators of PKB
TW200911798A (en) 2007-08-02 2009-03-16 Amgen Inc PI3 kinase modulators and methods of use
JP5324586B2 (ja) 2007-10-09 2013-10-23 エフ．ホフマン−ラ ロシュ アーゲー キラルシス−イミダゾリン
EP2231656A1 (en) 2007-12-19 2010-09-29 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
PE20091268A1 (es) 2007-12-19 2009-09-19 Amgen Inc Derivados heterociclicos como inhibidores de pi3 quinasa
US7776875B2 (en) 2007-12-19 2010-08-17 Hoffman-La Roche Inc. Spiroindolinone derivatives
EP2222296A2 (en) 2007-12-26 2010-09-01 Eisai R&D Management Co., Ltd. Ampa receptor antagonists and zonisamide for epilepsy
AU2009225984A1 (en) 2008-03-21 2009-09-24 Chlorion Pharma, Inc. Substituted pyrrolidine and piperidine compounds, derivatives thereof, and methods for treating pain
JP5530422B2 (ja) 2008-04-07 2014-06-25 アムジエン・インコーポレーテツド 細胞周期阻害薬としてのｇｅｍ−二置換およびスピロ環式アミノピリジン／ピリミジン
JP5599783B2 (ja) 2008-05-30 2014-10-01 アムジエン・インコーポレーテツド Ｐｉ３キナーゼの阻害薬
GB0811643D0 (en) 2008-06-25 2008-07-30 Cancer Rec Tech Ltd New therapeutic agents
TW201011009A (en) 2008-09-15 2010-03-16 Priaxon Ag Novel pyrrolidin-2-ones
JP5658157B2 (ja) 2008-09-18 2015-01-21 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 置換ピロリジン−２−カルボキサミド
US20110263647A1 (en) 2009-01-15 2011-10-27 Amgen Inc. Fluoroisoquinoline substituted thiazole compounds and methods of use
JP2012518037A (ja) 2009-02-18 2012-08-09 アムジエン・インコーポレーテツド ｍＴＯＲキナーゼ阻害剤としてのインドール／ベンゾイミダゾール化合物
CA2755285C (en) 2009-03-20 2014-02-11 Yunxin Y. Bo Inhibitors of pi3 kinase
US8076482B2 (en) 2009-04-23 2011-12-13 Hoffmann-La Roche Inc. 3,3′-spiroindolinone derivatives
UY32582A (es) 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
AU2010249040B2 (en) 2009-05-13 2013-08-22 Amgen Inc. Heteroaryl compounds as PIKK inhibitors
EA201270013A1 (ru) 2009-06-25 2012-06-29 Амген Инк. Гетероциклические соединения и их применение
AU2010266064A1 (en) 2009-06-25 2012-01-19 Amgen Inc. 4H - pyrido [1, 2 - a] pyrimidin - 4 - one derivatives as PI3 K inhibitors
JP2012531438A (ja) 2009-06-25 2012-12-10 アムジエン・インコーポレーテツド 複素環式化合物およびその使用
AU2010265971B2 (en) 2009-06-25 2014-08-14 Amgen Inc. Heterocyclic compounds and their uses as inhibitors of PI3 K activity
BR112012008075A2 (pt) 2009-08-26 2016-03-01 Novartis Ag compostos de heteroarila tetrassubstituídos e seu uso como moduladores de mdm2 e/ou mdm4
US8088815B2 (en) 2009-12-02 2012-01-03 Hoffman-La Roche Inc. Spiroindolinone pyrrolidines
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
CN102153557B (zh) 2011-01-21 2013-03-20 中国科学院上海有机化学研究所 具有乙二胺骨架的多手性中心氮杂环卡宾前体盐、合成方法及用途
WO2013049250A1 (en) 2011-09-27 2013-04-04 Amgen Inc. Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer
MX362896B (es) 2013-02-19 2019-02-22 Amgen Inc Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cáncer.
EP2961735B1 (en) 2013-02-28 2017-09-27 Amgen Inc. A benzoic acid derivative mdm2 inhibitor for the treatment of cancer
CA2906538C (en) 2013-03-14 2021-02-02 Ana Gonzalez Buenrostro Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer
JOP20200296A1 (ar) 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط

Also Published As

Publication number Publication date
HRP20240055T1 (hr) 2024-03-29
BR112012030923B8 (pt) 2022-01-25
KR20180059574A (ko) 2018-06-04
CN105153014B (zh) 2021-06-01
US20170144971A1 (en) 2017-05-25
SI2576510T1 (sl) 2015-06-30
DK3483143T3 (da) 2024-01-15
DK2927213T3 (en) 2019-03-11
KR101456801B1 (ko) 2014-10-31
TW201434816A (zh) 2014-09-16
ES2717306T3 (es) 2019-06-20
CN103180296A (zh) 2013-06-26
TWI519519B (zh) 2016-02-01
RS54030B1 (en) 2015-10-30
MX343587B (es) 2016-11-10
DK2576510T3 (en) 2015-06-29
AU2011261263C1 (en) 2014-05-29
ZA201400948B (en) 2015-06-24
ES2971445T3 (es) 2024-06-05
SI3483143T1 (sl) 2024-03-29
IL233411A (en) 2017-08-31
TWI433844B (zh) 2014-04-11
PL2576510T3 (pl) 2015-10-30
US20240300892A1 (en) 2024-09-12
NZ627385A (en) 2016-02-26
IL246296A0 (en) 2016-07-31
MX2012014044A (es) 2013-05-22
KR20230156431A (ko) 2023-11-14
AR082763A1 (es) 2013-01-09
SI2927213T1 (sl) 2019-04-30
HK1215707A1 (zh) 2016-09-09
IL233411A0 (en) 2014-08-31
MA34342B1 (fr) 2013-06-01
IL295076A (en) 2022-09-01
UY39338A (es) 2021-08-31
EP4092012A1 (en) 2022-11-23
CA2799972C (en) 2020-08-25
CY1121265T1 (el) 2020-05-29
TWI582076B (zh) 2017-05-11
BR122020013151B1 (pt) 2022-02-22
IL277579A (en) 2020-11-30
KR20200063255A (ko) 2020-06-04
EP2927213A1 (en) 2015-10-07
HRP20190273T1 (hr) 2019-04-05
JP2014062093A (ja) 2014-04-10
CA3060703A1 (en) 2011-12-08
NZ604074A (en) 2014-11-28
SG10202006923RA (en) 2020-08-28
PL3483143T3 (pl) 2024-03-25
EP3483143A1 (en) 2019-05-15
PL2927213T3 (pl) 2019-06-28
US20140011796A1 (en) 2014-01-09
CR20120659A (es) 2013-03-11
KR20140091009A (ko) 2014-07-18
ES2540992T3 (es) 2015-07-15
KR20220083817A (ko) 2022-06-20
LT3483143T (lt) 2024-02-12
CA2799972A1 (en) 2011-12-08
WO2011153509A1 (en) 2011-12-08
US8569341B2 (en) 2013-10-29
PE20130229A1 (es) 2013-03-22
PT3483143T (pt) 2024-01-23
US20190062276A1 (en) 2019-02-28
EP2576510B1 (en) 2015-04-29
ME03322B (me) 2019-10-20
US20220169611A1 (en) 2022-06-02
US20210179560A1 (en) 2021-06-17
HK1186462A1 (en) 2014-03-14
CA3157177C (en) 2023-11-07
CN105153014A (zh) 2015-12-16
CA3060703C (en) 2022-08-02
US9593129B2 (en) 2017-03-14
JP2016147891A (ja) 2016-08-18
RS58366B1 (sr) 2019-03-29
LT2927213T (lt) 2019-04-25
IL265278B (en) 2021-01-31
IL223201A (en) 2015-05-31
UA110481C2 (en) 2016-01-12
HRP20150704T1 (hr) 2015-08-14
AU2011261263B2 (en) 2013-11-21
CA3207676A1 (en) 2011-12-08
RS65141B1 (sr) 2024-02-29
EP2576510A1 (en) 2013-04-10
PT2576510E (pt) 2015-07-01
IL277579B (en) 2022-09-01
BR112012030923B1 (pt) 2021-12-28
CN103180296B (zh) 2015-05-27
SG186147A1 (en) 2013-01-30
US9296736B2 (en) 2016-03-29
BR112012030923A2 (pt) 2016-11-08
JP5420797B2 (ja) 2014-02-19
KR20190058694A (ko) 2019-05-29
KR101863407B1 (ko) 2018-06-29
EA201291356A1 (ru) 2013-06-28
TN2012000559A1 (en) 2014-04-01
HUE041488T2 (hu) 2019-05-28
PH12016501048A1 (en) 2017-05-29
MX337178B (es) 2016-02-15
FI3483143T3 (fi) 2024-01-15
US20140315895A1 (en) 2014-10-23
UY33430A (es) 2011-12-30
JP5908446B2 (ja) 2016-04-26
KR20210068144A (ko) 2021-06-08
ME02150B (me) 2015-10-20
SG10202112488SA (en) 2021-12-30
CO6710897A2 (es) 2013-07-15
JP6077695B2 (ja) 2017-02-08
AU2011261263A1 (en) 2012-12-13
KR20140032929A (ko) 2014-03-17
CA3157177A1 (en) 2011-12-08
SMT201500168B (it) 2015-09-07
EP2927213B1 (en) 2018-11-14
EP3483143B1 (en) 2023-10-18
MY202394A (en) 2024-04-25
HUE066050T2 (hu) 2024-07-28
JO2998B1 (ar) 2016-09-05
TW201211020A (en) 2012-03-16
EP3483143A8 (en) 2020-04-15
IL223201A0 (en) 2013-02-03
US20110319378A1 (en) 2011-12-29
HK1182711A1 (en) 2013-12-06
JP2013530958A (ja) 2013-08-01
IL265278A (en) 2019-05-30
US20160137667A1 (en) 2016-05-19
CL2016001733A1 (es) 2017-05-12
TW201609649A (zh) 2016-03-16
SG10201604817QA (en) 2016-08-30
CL2012003415A1 (es) 2013-08-09
EA023004B1 (ru) 2016-04-29

Similar Documents

Publication Publication Date Title
IL277579A (en) Piperidinone derivatives as MDM2 inhibitors for cancer therapy
HRP20150692T8 (en) Substituted benzopyrazin derivatives as fgfr kinase inhibitors for the treatment of cancer diseases
IL232128B (en) Tor kinase inhibitors for cancer treatment
EP2542081A4 (en) COMPOSITIONS FOR CANCER TREATMENT
IL221823A (en) Pipridine-4-Il-Aztidine Derivatives as Jack 1 Suppressors
EP2554175A4 (en) COMPOSITION FOR THE TREATMENT OF A DESIRED PART
SI2605764T1 (sl) Sestavki za zdravljenje raka
EP2608671A4 (en) COMPOUNDS USED IN THE TREATMENT OF CANCER
EP2897607A4 (en) BETA-HYDROLASE INHIBITORS FOR THE TREATMENT OF CANCER
IL215199A0 (en) Thia-triaza-cyclopentazulenes as pi3-kinases inhibitors for the treatment of cancer
AU2012901199A0 (en) Kinase inhibitors for the Treatment of Cancer